Maximal extent of resection (EOR) of glioblastoma (GBM) is associated with greater progression free survival (PFS) and improved patient outcomes. Recently, a novel surgical system has been developed that includes a 2D, robotically-controlled exoscope and brain tractography display. The purpose of this study was to assess outcomes in a series of patients with GBM undergoing resections using this surgical exoscope.
A retrospective review was conducted for robotic exoscope assisted GBM resections between 2017 and 2019. EOR was computed from volumetric analyses of pre- and post-operative MRIs. Demographics, pathology/MGMT status, imaging, treatment, and outcomes data were collected. The relationship between these perioperative variables and discharge disposition as well as progression-free survival (PFS) was explored.
A total of 26 patients with GBM (median age = 57 years) met inclusion criteria, comprising a total of 28 cases. Of these, 22 (79%) tumors were in eloquent regions, most commonly in the frontal lobe (14 cases, 50%). The median pre- and post-operative volumes were 24.0 cc and 1.3 cc, respectively. The median extent of resection for the cohort was 94.8%, with 86% achieving 6-month PFS. The most common neurological complication was a motor deficit followed by sensory loss, while 8 patients (29%) were symptom-free.
The robotic exoscope is safe and effective for patients undergoing GBM surgery, with a majority achieving large-volume resections. These patients experienced complication profiles similar to those undergoing treatment with the traditional microscope. Further studies are needed to assess direct comparisons between exoscope and microscope-assisted GBM resection.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330
Cummings SM, Savitz LA, Konrad TR (2001) Reported response rates to mailed physician questionnaires. Health Serv Res 35(6):1347–1355
Fernandes C, Costa A, Osório L et al (2017) Current standards of care in glioblastoma therapy. In: De Vleeschouwer S (ed) Glioblastoma. Codon Publications, Brisbane
Chaichana KL, Jusue-Torres I, Navarro-Ramirez R et al (2014) Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-Oncol 16(1):113–122. https://doi.org/10.1093/neuonc/not137
Majewska P, Ioannidis S, Raza MH, Tanna N, Bulbeck H, Williams M (2017) Postprogression survival in patients with glioblastoma treated with concurrent chemoradiotherapy: a routine care cohort study. CNS Oncol 6(4):307–313. https://doi.org/10.2217/cns-2017-0001
Brown TJ, Brennan MC, Li M et al (2016) Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol 2(11):1460–1469. https://doi.org/10.1001/jamaoncol.2016.1373
Stummer W (2015) Response to journal club: 5-aminolevulinic acid-derived tumor fluorescence: the diagnostic accuracy of visible fluorescence qualities as corroborated by spectrometry and histology and postoperative imaging. Neurosurgery 76(2):230–231. https://doi.org/10.1227/NEU.0000000000000629
Young RM, Jamshidi A, Davis G, Sherman JH (2015) Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med 3(9):121. https://doi.org/10.3978/j.issn.2305-5839.2015.05.10
Haj A, Doenitz C, Schebesch K-M et al (2017) Extent of resection in newly diagnosed glioblastoma: impact of a specialized neuro-oncology care center. Brain Sci. https://doi.org/10.3390/brainsci8010005
Lacroix M, Abi-Said D, Fourney DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95(2):190–198. https://doi.org/10.3171/jns.2001.95.2.0190
Sanai N, Polley M-Y, McDermott MW, Parsa AT, Berger MS (2011) An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115(1):3–8. https://doi.org/10.3171/2011.2.jns10998
Orringer D, Lau D, Khatri S et al (2012) Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg 117(5):851–859. https://doi.org/10.3171/2012.8.JNS12234
Chaichana KL, Cabrera-Aldana EE, Jusue-Torres I et al (2014) When gross total resection of a glioblastoma is possible, how much resection should be achieved? World Neurosurg 82(1–2):e257–265. https://doi.org/10.1016/j.wneu.2014.01.019
Li YM, Suki D, Hess K, Sawaya R (2016) The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg 124(4):977–988. https://doi.org/10.3171/2015.5.JNS142087
Jermyn M, Mok K, Mercier J et al (2015) Intraoperative brain cancer detection with Raman spectroscopy in humans. Sci Transl Med. 7(274):274ra19–274ra19. https://doi.org/10.1126/scitranslmed.aaa2384
Zhang DY, Singhal S, Lee JYK (2019) Optical principles of fluorescence-guided brain tumor surgery: a practical primer for the neurosurgeon. Neurosurgery 85(3):312–324. https://doi.org/10.1093/neuros/nyy315
Acerbi F, Broggi M, Schebesch K-M et al (2018) Fluorescein-guided surgery for resection of high-grade gliomas: a multicentric prospective Phase II Study (FLUOGLIO). Clin Cancer Res 24(1):52–61. https://doi.org/10.1158/1078-0432.CCR-17-1184
Díez Valle R, Hadjipanayis CG, Stummer W (2019) Established and emerging uses of 5-ALA in the brain: an overview. J Neurooncol 141(3):487–494. https://doi.org/10.1007/s11060-018-03087-7
Hadjipanayis CG, Stummer W, Sheehan JP (2019) 5-ALA fluorescence-guided surgery of CNS tumors. J Neurooncol 141(3):477–478. https://doi.org/10.1007/s11060-019-03109-y
Doglietto F, Belotti F, Panciani P, Poliani PL, Fontanella MM (2020) High-definition 3-dimensional exoscope for 5-ALA glioma surgery: 3-dimensional operative video. Oper Neurosurg. https://doi.org/10.1093/ons/opz139
Oertel JM, Burkhardt BW (2017) Vitom-3D for exoscopic neurosurgery: initial experience in cranial and spinal procedures. World Neurosurg 105:153–162. https://doi.org/10.1016/j.wneu.2017.05.109
Langer DJ, White TG, Schulder M, Boockvar JA, Labib M, Lawton MT (2019) Advances in intraoperative optics: a brief review of current exoscope platforms. Oper Neurosurg Hagerstown. https://doi.org/10.1093/ons/opz276
Beez T, Munoz-Bendix C, Beseoglu K, Steiger H-J, Ahmadi SA (2018) First clinical applications of a high-definition three-dimensional exoscope in pediatric neurosurgery. Cureus 10(1):e2108. https://doi.org/10.7759/cureus.2108
Muhammad S, Lehecka M, Niemelä M (2019) Preliminary experience with a digital robotic exoscope in cranial and spinal surgery: a review of the Synaptive Modus V system. Acta Neurochir (Wien) 161(10):2175–2180. https://doi.org/10.1007/s00701-019-03953-x
Waqas M, Enam SA, Hashmi FA, Mubarak F, Arain F (2017) Video microscope robotic arm-assisted, neuronavigation-guided glioma resection and regional sampling. Cureus 9(10):e1738. https://doi.org/10.7759/cureus.1738
Ottenhausen M, Krieg SM, Meyer B, Ringel F (2015) Functional preoperative and intraoperative mapping and monitoring: increasing safety and efficacy in glioma surgery. Neurosurg Focus 38(1):E3. https://doi.org/10.3171/2014.10.FOCUS14611
Lakomkin N, Hadjipanayis CG (2018) Fluorescence-guided surgery for high-grade gliomas. J Surg Oncol 118(2):356–361. https://doi.org/10.1002/jso.25154
Hatiboglu MA, Weinberg JS, Suki D et al (2009) Impact of intraoperative high-field magnetic resonance imaging guidance on glioma surgery: a prospective volumetric analysis. Neurosurgery. 64(6):1073–1081. https://doi.org/10.1227/01.NEU.0000345647.58219.07. (discussion 1081)
Dohlman GF (1969) Carl Olof Nylén and the birth of the otomicroscope and microsurgery. Arch Otolaryngol 90(6):813–817. https://doi.org/10.1001/archotol.1969.00770030815025
Donaghy RM (1979) The history of microsurgery in neurosurgery. Clin Neurosurg 26:619–625. https://doi.org/10.1093/neurosurgery/26.cn_suppl_1.619
Buncke HJ (1995) Forty years of microsurgery: what’s next? J Hand Surg 20(3 Pt 2):S34–45. https://doi.org/10.1016/s0363-5023(95)80168-5
Stummer W, Stocker S, Wagner S et al (1998) Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 42(3):518–525. https://doi.org/10.1097/00006123-199803000-00017. (discussion 525–526)
Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93(6):1003–1013. https://doi.org/10.3171/jns.2000.93.6.1003
Neira JA, Ung TH, Sims JS et al (2017) Aggressive resection at the infiltrative margins of glioblastoma facilitated by intraoperative fluorescein guidance. J Neurosurg 127(1):111–122. https://doi.org/10.3171/2016.7.JNS16232
Laurent D, Freedman R, Cope L et al (2019) Impact of extent of resection on incidence of postoperative complications in patients with glioblastoma. Neurosurgery. https://doi.org/10.1093/neuros/nyz313
Abecassis IJ, Cordy B, Durfy S et al (2020) Evaluating angioarchitectural characteristics of glial and metastatic brain tumors with conventional magnetic resonance imaging. J Clin Neurosci. https://doi.org/10.1016/j.jocn.2020.04.051
Karsy M, Yoon N, Boettcher L et al (2018) Surgical treatment of glioblastoma in the elderly: the impact of complications. J Neurooncol 138(1):123–132. https://doi.org/10.1007/s11060-018-2777-9
Pessina F, Navarria P, Cozzi L et al (2017) Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. J Neurooncol 135(1):129–139. https://doi.org/10.1007/s11060-017-2559-9
Lakomkin N, Hadjipanayis CG (2018) Non-routine discharge disposition is associated with post-discharge complications and 30-day readmissions following craniotomy for brain tumor resection. J Neurooncol 136(3):595–604. https://doi.org/10.1007/s11060-017-2689-0
Dasenbrock HH, Liu KX, Devine CA et al (2015) Length of hospital stay after craniotomy for tumor: a national surgical quality improvement program analysis. Neurosurg Focus 39(6):E12. https://doi.org/10.3171/2015.10.FOCUS15386
Conflict of interest
Constantinos Hadjipanayis is a consultant for NX Development Corp. (NXDC) and Synaptive Medical Inc. He receives royalties from NXDC.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Baron, R.B., Lakomkin, N., Schupper, A.J. et al. Postoperative outcomes following glioblastoma resection using a robot-assisted digital surgical exoscope: a case series. J Neurooncol 148, 519–527 (2020). https://doi.org/10.1007/s11060-020-03543-3
- Extent of resection
- Progression-free survival